Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial

摘要: The aim of the present study was to examine effects green tea epigallocatechin-3-gallate (EGCG) on changes in body composition, energy and substrate metabolism, cardiometabolic risk factors liver function enzymes after an energy-restricted diet intervention obese women. In randomised, double-blind, placebo-controlled study, eighty-three (30 kg/m² > BMI < 40 kg/m²) pre-menopausal women consumed 300 mg/d EGCG or placebo (lactose). We measured weight adiposity (dual-energy X-ray absorptiometry), expenditure fat oxidation rates (indirect calorimetry), blood lipid levels (TAG, total cholesterol, LDL-cholesterol HDL-cholesterol), insulin resistance, C-reactive protein markers (aspartate aminotransferase, alanine alkaline phosphatase, γ-glutamyltransferase, urea, bilirubin 2-keto[1-¹³C]isocaproate oxidation) before control groups. did not find any significant difference (-0.3 kg, 95% CI -5.0, 4.3), mass (-0.7 -3.5, 2.1), (0.3 kJ/kg per d, -3.1, 2.7) (-0.1 g/min, -0.03, 0.01) homeostasis assessment model for resistance (0.2, -0.2, 0.7), cholesterol (-0.21 mmol/l, -0.55, 0.13), (-0.15 -0.50, 0.20), TAG (-0.4 -0.56, 0.29) between conclusion, results suggest that dietary supplementation with 12 weeks enhance diet-induced reductions, improve weight-loss-induced Caucasian intake cause adverse effect biomarkers.